[SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes].

André Scheen et al.PubMed ↗

What the trial testedrandomised · 2026

Randomised comparison

−16%−25% to −6%

Bigger than 5 in 10 for all-cause mortality

As reported

HR 0.84, 95% CI 0.75–0.94 · the paper's word: All-cause mortality

the abstract, start to end

… after four years of median follow-up (HR 0.84 ; 95 % CI 0.75 to 0.94; …

← favours treatmentfavours comparator →

could be chance

All-cause mortality

HR 0.840.75–0.94

GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsAll-cause mortality

GIP/GLP-1 & amylin agonists × all-cause mortalityhelps?one trial

unlikelylikely

0.350.25 without it

GLP-1 receptor agonists × all-cause mortalityhelps?replicated

unlikelylikely

0.880.86 without it

← favours treatmentfavours comparator →

this papermore certainless certain

1 / 5